Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 11, Issue -, Pages -Publisher
BIOMED CENTRAL LTD
DOI: 10.1186/s13045-017-0551-7
Keywords
Pancreatic ductal adenocarcinoma; Novel regimens; Biomarkers; Combination therapies
Categories
Funding
- National Natural Science Foundation of China [81370065, 81372653]
- basic research project of the Science and Technology Commission of Shanghai Municipality [15JC1401200]
- National Science Fund for Distinguished Young Scholars [81625016]
Ask authors/readers for more resources
A poor prognosis of pancreatic ductal adenocarcinoma (PDAC) associated with chemoresistance has not changed for the past three decades. A multidisciplinary diagnosis followed by surgery and chemo(radiation) therapy is the main treatment approach. However, gemcitabine-and 5-fluorouracil-based therapies did not present satisfying outcomes. Novel regimens targeting pancreatic cancer cells, the tumor microenvironment, and immunosuppression are emerging. Biomarkers concerning the treatment outcome and patient selection are being discovered in preclinical or clinical studies. Combination therapies of classic chemotherapeutic drugs and novel agents or novel therapeutic combinations might bring hope to the dismal prognosis for PDAC patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available